GSK plc vs Vanguard Real Estate Index Fund ETF — how do they compare? GSK plc trades at $50.37 (market cap $102.60B), while Vanguard Real Estate Index Fund ETF trades at $97.36. The key difference: GSK plc pays a 3.57% dividend while Vanguard Real Estate Index Fund ETF pays none, and Vanguard Real Estate Index Fund ETF is trading nearer its 52-week high, GSK plc nearer its low. Which is the better fit depends on your goals.
| GSK | VNQ | |
|---|---|---|
Market Cap | $102.60B | — |
Sector | Health | — |
52-Week High | $61.18 | $100.95 |
52-Week Low | $38.22 | $87.00 |
Enterprise Value | $123.04B | — |
Dividend Yield | 3.57% | — |
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
VNQ, the Vanguard Real Estate ETF, trades at $97.31, up 0.21% on the day, but technical indicators signal a bearish trend with moving averages and overall signals pointing lower. The ETF's financial ratios are not disclosed in the provided data, limiting fundamental assessment. Recent news highlights institutional selling, with firms like City Holding Co. and Bank of America reducing positions, while media comparisons focus on VNQ's U.S. REIT exposure and low fees versus global alternatives.
Outlook remains cautious due to bearish technicals and institutional outflows, though the neutral oscillator reading and upcoming dividend in June 2026 offer some balance. Risks include interest rate sensitivity and real estate market volatility, but the ETF's low expense ratio and diversification provide a defensive income option for long-term investors amid economic uncertainty.
Trailing returns across standard periods
Latest headlines on both assets
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Real Estate 25/50 Index, an index made up of stocks of large, mid-size, and small US companies within the real estate sector. The Advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VNQ →